Litcius/Paper detail

Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study

Johan Lyth, Emma Svennberg, Lars Bernfort, Mattias Aronsson, Viveka Frykman, Faris Al‐Khalili, Leif Friberg, Mårten Rosenqvist, Johan Engdahl, Lars‐Åke Levin

2022European Heart Journal70 citationsDOIOpen Access PDF

Abstract

AIMS: Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are based on assumptions of long-term clinical effects. The STROKESTOP study, which randomised 27 975 persons aged 75/76 years into a screening invitation group and a control group, has a median follow-up time of 6.9 years. The aim of this study was to estimate the cost-effectiveness of population-based screening for AF using clinical outcomes. METHODS AND RESULTS: The analysis is based on a Markov cohort model. The prevalence of AF, the use of oral anticoagulation, clinical event data, and all-cause mortality were taken from the STROKESTOP study. The cost for clinical events, age-specific utilities, utility decrement due to stroke, and stroke death was taken from the literature. Uncertainty in the model was considered in a probabilistic sensitivity analysis. Per 1000 individuals invited to the screening, there were 77 gained life years and 65 gained quality-adjusted life years. The incremental cost was €1.77 million lower in the screening invitation group. Gained quality-adjusted life years to a lower cost means that the screening strategy was dominant. The result from 10 000 Monte Carlo simulations showed that the AF screening strategy was cost-effective in 99.2% and cost-saving in 92.7% of the simulations. In the base-case scenario, screening of 1000 individuals resulted in 10.6 [95% confidence interval (CI): -22.5 to 1.4] fewer strokes (8.4 ischaemic and 2.2 haemorrhagic strokes), 1.0 (95% CI: -1.9 to 4.1) more cases of systemic embolism, and 2.9 (95% CI: -18.2 to 13.1) fewer bleedings associated with hospitalization. CONCLUSION: Based on the STROKESTOP study, this analysis shows that a broad AF screening strategy in an elderly population is cost-effective. Efforts should be made to increase screening participation.

Topics & Concepts

MedicineAtrial fibrillationStroke (engine)Quality-adjusted life yearCost effectivenessConfidence intervalCohortPopulationQuality of life (healthcare)Cost-effectiveness analysisEmergency medicinePediatricsInternal medicineNursingRisk analysis (engineering)Environmental healthEngineeringMechanical engineeringAtrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementChronic Disease Management Strategies